Latest filing published 10 Jul 2026 for Contineum Therapeutics, Inc., €899.
Daniel S. Lorrain (senior executive) discloses dealings in Contineum Therapeutics, Inc. to SEC (Form 4). Between 18 November 2024 and 9 July 2026, the trades on record add up to 16 filings.
No open-market purchase appears, only 11 sales worth €430k. Other entries cover 5 option exercises. So far in 2026, the count stands at no purchases and 8 sales.
The latest filing, published on 10 July 2026, reports an option exercise of €899 in Contineum Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
16 of 16 declarations